Kadri Toome

Kadri Toome

Auto-generated profile, based on publicly available information

Kadri Toome

Department of Laboratory Genetics, Genetics and Personalized Medicine Clinic, Tartu University Hospital, Tartu, Estonia

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2026 in Acta Oncologica
Verified
Journal Article
Open access
MTMikk Tooming
Mikk Tooming
KRKadri Rekker
Kadri Rekker
KTKadri Toome
Kadri Toome
LRLaura Roht
Laura Roht
PLPiret Laidre
Piret Laidre
TKTiina Kahre
Tiina Kahre
Background and purpose: This retrospective study provides Estonia’s first nationwide overview of pathogenic and likely pathogenic variants in ovarian cancer (OC) using routine tumor molecular profiling. The aim was to characterize the mutational landscape, identify clinically actionable alterations, and evaluate the integration of germline testing.Patient/material and methods: A total of 339 OC tumor samples underwent next‑generation sequencing-based profiling. Clinical characteristics, histological subtype, and prior germline testing were recorded. Variants were classified according to clinical‑actionability levels, and homologous recombination deficiency (HRD) was assessed in high‑grade serous OC cases.Results: The mean age at diagnosis was 62.4 ± 12.5 years, and high‑grade serous OC accounted for 82.0% of cases. Clinically actionable alterations (OncoKB Level 1&2) were detected in 37.5% of patients, most frequently involving BRCA1, BRCA2, KRAS, and BRAF. Additional therapeutic targets were identified across diverse biomarkers. HRD was present in 53.2% of tested high‑grade serous tumors. Germline testing had been performed in 41.9% of patients, revealing pathogenic or likely pathogenic variants in 22.5%, predominantly in BRCA1 and BRCA2.Interpretation: This study outlines the mutational spectrum of OC in Estonia and demonstrates a substantial prevalence of actionable alterations and HRD. The findings highlight the value of comprehensive tumor profiling to support precision‑medicine approaches and improve individualized patient management in Estonia.

17 June 2026 in npj Precision Oncology
Verified
Journal Article
Open access
Sigve NakkenSigve Nakken
Sigve Nakken
AEAnders Edsjö
Anders Edsjö
JLJanne Lehtiö
Janne Lehtiö
VNVigdis Nygaard
Vigdis Nygaard
PRPaul Roepman
Paul Roepman
EHEivind Hovig
Eivind Hovig
Molecular tumor boards are supported by clinical decision support system (CDSS) tools for the interpretation of complex molecular data towards personalized treatments. Current CDSS tools are genomics-focused and characterized by tight couplings between data ingestion, guideline-based reasoning logic and curated knowledgebases. Next-generation CDSS solutions should integrate multimodal data and learn from outcomes in an interoperable ecosystem, leveraging explainable, trustworthy output from AI models through rigorous clinical validation processes.